Key result
Edoxaban is at least as effective as warfarin for preventing stroke or systemic embolism in nonvalvular atrial fibrillation and treating venous thromboembolism, with a lower risk of bleeding.
Why the study?
Does edoxaban reduce the risk of thromboembolic complications compared to warfarin in patients with nonvalvular atrial fibrillation or venous thromboembolism?
Does edoxaban reduce the risk of thromboembolic complications compared to warfarin in patients with nonvalvular atrial fibrillation or venous thromboembolism?
Edoxaban is an effective and safe alternative to warfarin for stroke prevention in nonvalvular atrial fibrillation and for the treatment of venous thromboembolism, offering a lower risk of bleeding.
Edoxaban matches warfarin efficacy in nonvalvular AF and VTE; leaves open optimal real-world dosing and adherence.
Edoxaban is a once-daily oral inhibitor of factor Xa, currently indicated to reduce the risk of stroke or systemic embolism in nonvalvular atrial fibrillation patients and for the treatment and prevention of venous thromboembolism (EMA, FDA and Japan). The ENGAGE AF-TIMI 48 and the Hokusai-VTE trials demonstrated that edoxaban was at least as effective as warfarin for the prevention of stroke or systemic embolism in nonvalvular atrial fibrillation patients, as well as for the prevention and treatment of venous thromboembolism, but with a lesser risk of bleeding in both cases. In addition, it seems a cost-effective strategy for the management of this population. In this review, the implications of the most recent available evidence about edoxaban in clinical practice will be updated.
No takes yet. Share an insight, caveat, or question.
Barrios et al. (2016) conducted a review in Nonvalvular atrial fibrillation and venous thromboembolism. Edoxaban vs. warfarin was evaluated on Stroke or systemic embolism, and venous thromboembolism. Edoxaban is at least as effective as warfarin for preventing stroke or systemic embolism in nonvalvular atrial fibrillation and treating venous thromboembolism, with a lower risk of bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: